Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 8:07 PM ET


Company Overview of Crescendo Bioscience, Inc.

Company Overview

Crescendo Bioscience, Inc., a molecular diagnostics company, develops and commercializes quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases in the United States. The company offers Vectra DA, a multi-biomarker blood test for RA disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Crescendo Bioscience, Inc. was formerly known as Riley Genomics, Inc. and changed its name to Crescendo Bioscience, Inc. in June 2005. The company was founded in 2002 and is based in South San Francisco, California. Crescendo Bioscience, In...

341 Oyster Point Boulevard

South San Francisco, CA 94080

United States

Founded in 2002





Key Executives for Crescendo Bioscience, Inc.

Age: 58
Co-Founder and Scientific Advisor
Chief Financial Officer
Age: 57
Chief Operating Officer
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2015.

Crescendo Bioscience, Inc. Key Developments

Crescendo Bioscience Appoints Elena Hitraya as Chief Medical Officer, Effective October 1, 2015

Crescendo Bioscience announced that Elena Hitraya M.D., Ph.D., has joined the company as the chief medical officer of Crescendo Bioscience, effective October 1, 2015. She will report to Bernie Tobin, president of Crescendo Bioscience. In her new role, Dr. Hitraya will lead efforts to provide professional education initiatives and to expand market access for Vectra DA and the company's pipeline of autoimmune products. She will also be instrumental in efforts to develop other autoimmune products beyond rheumatoid arthritis. Dr. Hitraya comes to Crescendo with more than 25 years of experience in rheumatology and immunology, and she has published extensively. Over the past 11 years, she has held several leadership positions at Genentech, including most recently as group medical director of rheumatology/immunology for the Genentech/Roche group.

Myriad Genetics Appoints Bernard Tobin as President of Crescendo Bioscience, Effective January 5, 2015

Myriad Genetics, Inc. announced the appointment of Bernard Tobin as president of Crescendo Bioscience, effective January 5, 2015. He will succeed William Hagstrom, who has chosen to pursue new start-up business and social venture opportunities. Tobin will report to Peter Meldrum, president and CEO, Myriad Genetics. Hagstrom will remain with the company until January 2, 2015 to ensure a smooth transition in leadership. Tobin has held several senior positions at Amgen over the past seven years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence.

Crescendo Bioscience Presents New Clinical Data on Vectra(R) DA at ACR

Crescendo Bioscience presented new data that showed Vectra(R) DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis (RA), such as C-reactive protein (CRP). The oral presentation was featured at the 2014 American College of Rheumatology (ACR) Annual Meeting in Boston, Massachusetts. The study included 143 patients with RA who had received a stable treatment and were enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry in the United States. Patients were evaluated at their initial visit in the BRASS registry for the Vectra DA score and conventional measures of disease activity, including CRP, DAS28-CRP, CDAI, SDAI and RAPID3, and provided X-rays of hands and wrists at approximately the initial visit and two years later. These data were used to assess the relationship between disease activity and the amount of subsequent new joint damage seen on X-rays (radiographic progression). Another study featured at ACR provided an analysis of radiographic progression in patients with early RA from the Swedish Farmacotherapy (SWEFOT) clinical trial. The Vectra DA test was used to evaluate 220 patients for progression from baseline to Year 1 and from baseline to Year 2. In addition, progression from Year 1 to Year 2 was evaluated for 133 patients who had inadequate initial responses to methotrexate and were treated from month three with the addition of a TNF inhibitor or with triple therapy using methotrexate, sulfasalazine and hydroxychloroquine.

Similar Private Companies By Industry

Company Name Region
Axial Biotech, Inc. United States
Velcera, Inc. United States
Syndax Pharmaceuticals, Inc. United States
Caliper Discovery Alliances & Services United States
Cytocom, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Crescendo Bioscience, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at